Advertisement

Pharmacy World & Science

, Volume 30, Issue 5, pp 544–549 | Cite as

An evaluation of the effects of gatifloxacin on glucose homeostasis

  • Ahunna J. OnyenwenyiEmail author
  • Almut G. Winterstein
  • Randy C. Hatton
Research Article

Abstract

Introduction The United States labeling for gatifloxacin has been updated to include contradictions related to its reported association with dysglycemia. However, adequately controlled studies in acute care settings assessing the magnitude and clinical determinants of dysglycemia are lacking. Objectives To compare the hypoglycemic and hyperglycemic effects of gatifloxacin with ceftriaxone in hospitalized patients. Methods A retrospective cohort study of hospitalized adult (≥18 years) patients admitted with Community Acquired Pneumonia (CAP) or Acute Exacerbation of Chronic Bronchitis (AECB) in a US tertiary care hospital between 7/1/01 and 12/31/04 treated with gatifloxacin or ceftriaxone during hospital admission. Outcomes of interests were incidence of hypoglycemia (blood glucose levels <46 mg/dL) or hyperglycemia (>200 mg/dL) during up to 5 days of drug exposure. Risks for gatifloxacin and ceftriaxone were compared adjusting for variables previously reported to be independent predictors of hypoglycemia or hyperglycemia. Results 1504 patients met the study inclusion criteria. Compared to ceftriaxone, gatifloxacin was associated with an increased risk of hypoglycemia: (adjusted odds ratio (OR) 2.34, 95% confidence interval (CI) 1.4–4.0). The increased risk of hypoglycemia during exposure to gatifloxacin was similar in patients with and without a diagnosis of diabetes mellitus. Gatifloxacin was not associated with an increased risk for hyperglycemia (adjusted OR: 1.06 95% CI 0.8–1.4) considering the whole study cohort. However, stratification by diagnosis of diabetes, gatifloxacin treated patients appeared to have a reduced risk of hyperglycemia (adjusted OR: 0.4 95% CI 0.2–0.4) while non-diabetic gatifloxacin treated patients appeared to have an increased risk of hyperglycemia (adjusted OR: 1.64 95% CI 1.1–2.4). Conclusion The risk of dysglycemia with gatifloxacin in this population of hospitalized patients was not as high as previously reported in ambulatory patients. Although these results suggest gatifloxacin use is safer in acute care settings, we recommend that clinicians monitor blood glucose levels carefully or consider alternatives to gatifloxacin therapy whenever possible.

Keywords

Hypoglycemia Hyperglycemia Dysglycemia Glucose homeostasis Gatifloxacin Fluoroquinolones Ceftriaxone 

Notes

Acknowledgement

Financial support of the study

None

Conflict of interests

The authors have no conflict of interests to disclose.

References

  1. 1.
    Arce FC, Bhasin RS, Pasmantier R. Severe hyperglycemia during gatifloxacin therapy in patients without diabetes. Endocr Pract 2004;10:40–4. .PubMedGoogle Scholar
  2. 2.
    Baker SE, Hangii MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother 2002;36:1722–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Beste LA, Mersfelder TL. Hyperglycemia and gatifloxacin: a case report and summary of current literature. Am J Geriatr Pharmacother 2005;3:262–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Bhatia V, Bhatia R, Dhindsa S. Gatifloxacin-induced hyperglycemia. Endocr Pract 2004;10:86.PubMedGoogle Scholar
  5. 5.
    Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 2003;16:455–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Blommel AL, Lutes RA. Severe hyperglycemia during renally adjusted gatifloxacin therapy. Ann Pharmacother 2005;39:1349–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Brogan SE, Cahalan MK. Gatifloxacin as a possible cause of serious postoperative hypoglycemia. Anesth Analg 2005;101:635–6, table.PubMedCrossRefGoogle Scholar
  8. 8.
    Donaldson AR, Vandiver JR, Finch CK. Possible gatifloxacin-induced hyperglycemia. Ann Pharmacother 2004;38:602–5.PubMedCrossRefGoogle Scholar
  9. 9.
    LeBlanc M, Belanger C, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacotherapy 2004;24:926–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Stading JA, Chock AW, Skrabal MZ, Faulkner MA. Development of diabetes after gatifloxacin therapy. Am J Health Syst Pharm 2005;62:2293–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005;25:1296–302.PubMedCrossRefGoogle Scholar
  12. 12.
    Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Ishiwata Y, Sanada Y, Yasuhara M. Effects of gatifloxacin on serum glucose concentration in normal and diabetic rats. Biol Pharm Bull 2006;29:527–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000;20:76S–86S.PubMedCrossRefGoogle Scholar
  15. 15.
    Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000;20:49S–58S.PubMedCrossRefGoogle Scholar
  16. 16.
    Cruz Jentoft AJ, Villar I, Carreras P, Ribera JM. Unexpected hypoglycemia in hospitalized patients. Rev Clin Esp 1992;191:295–8.PubMedGoogle Scholar
  17. 17.
    Fischer KF, Lees JA, Newman JH. Hypoglycemia in hospitalized patients: causes and outcomes. N Engl J Med 1986;315:1245–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Kagansky N, Levy S, Rimon E, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003;163:1825–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Shilo S, Berezovsky S, Friedlander Y, Sonnenblick M. Hypoglycemia in hospitalized nondiabetic older patients. J Am Geriatr Soc 1998;46:978–82.PubMedGoogle Scholar
  20. 20.
    Stagnaro-Green A, Barton MK, Linekin PL, Corkery E, deBeer K, Roman SH. Mortality in hospitalized patients with hypoglycemia and severe hyperglycemia. Mt Sinai J Med 1995;62:422–6.PubMedGoogle Scholar
  21. 21.
    McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001;17:107–24.PubMedCrossRefGoogle Scholar
  22. 22.
    Coblio NA, Mowrey K, McCright P, Means H, McCormick MT. Use of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am J Health Syst Pharm 2004;61:2545–8.PubMedGoogle Scholar
  23. 23.
    Gavin JR III, Kubin R, Choudhri S, et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004;27:671–86.PubMedCrossRefGoogle Scholar
  24. 24.
    Hori S, Kizu J, Kawamura M. Effect of fluoroquinolones on plasma glucose levels in fasted and glucose-loaded mice. J Infect Chemother 2006;12:109–11.PubMedCrossRefGoogle Scholar
  25. 25.
    Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25:1303–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone 2003;Suppl 3:S29–S36.PubMedCrossRefGoogle Scholar
  27. 27.
    Clinical Trials.Gov. A controlled trial of a 4-month quinolone-containing regimen for the treatment of pulmonary tuberculosis. US National Institutes of Health. 9-20-0005. http://clinicaltrials.gov/ct2/show/NCT00216385?intr = %22Gatifloxacin%22 (4-5-2007).Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Ahunna J. Onyenwenyi
    • 1
    Email author
  • Almut G. Winterstein
    • 1
  • Randy C. Hatton
    • 2
  1. 1.Department of Pharmaceutical Outcomes and Policy, College of PharmacyUniversity of FloridaGainesvilleUSA
  2. 2.Shands Drug Information and Pharmacy Resource CenterUniversity of FloridaGainesvilleUSA

Personalised recommendations